In selling and marketing, spending increased 0.8 million, or 44%, primarily due to higher consulting fees associated with the CMS reimbursement progress and greater commercial activity as COVID-related restrictions are lifted, including trade show, travel, and personnel-related expenses.

Feb 23, 2023 / CEO / receipt, needs a key / Larry Jasinski, CEO | earnings call 2023-02-23 | transcript 182be31f-a1c2-4cf4-8fb5-3102084689a9 | chars 10610-10898 | segment 10

During a year when the pandemic continued longer than expected and the significant spike in the fourth quarter with the Omnicon variant, The company grew revenue for the year ended December 31st, 2021 to 5.97 million, a 36% increase year over year. We had 1.24 million in Q4 sales, which was a 2% increase over the prior year quarter. During 2021, the COVID-19 pandemic continued to impact our sales activities. Three key factors were one, Reduction in incoming leads over much of 2021 as trade shows and in-person demonstrations were very limited by COVID-19 restrictions. Two, our inability to train patients as many clinics remain closed, which prevented the six months plus cycle of moving patients through the system for Q4 conversion due to the ongoing pandemic. And three, further limitation of conversion of the trainings that were achieved to date due to the Omicron variant spike in Q4.

Feb 24, 2022 / CEO / receipt, needs a key / Larry Jasinski, CEO | earnings call 2022-02-24 | transcript 032ffd8d-a0ce-4c3f-951b-027ede529917 | chars 3209-4105 | segment 3

Our operating expenses will be level in almost all efforts beyond sales commission and travel expenses.

May 11, 2021 / CEO / receipt, needs a key / Larry Jasinski, CEO | earnings call 2021-05-11 | transcript 68946ba1-5b0e-4005-8deb-19627e97e653 | chars 5014-5117 | segment 5